{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:38:34Z","timestamp":1759333114503,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10072-022-06108-6","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T23:03:26Z","timestamp":1651964606000},"page":"5185-5187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-4826","authenticated-orcid":false,"given":"Ceren","family":"Alis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogukan Hazar","family":"Emre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-2852","authenticated-orcid":false,"given":"Feray","family":"Karaali Savrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-0850","authenticated-orcid":false,"given":"Aysegul","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-2249","authenticated-orcid":false,"given":"Nurten","family":"Uzun Adatepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"6108_CR1","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"6108_CR2","doi-asserted-by":"publisher","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al.;\u00a0REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.\u00a0Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"6108_CR3","doi-asserted-by":"publisher","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al; Regain Study Group (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60(1):14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","DOI":"10.1002\/mus.26447"},{"key":"6108_CR4","doi-asserted-by":"publisher","unstructured":"Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24(7):4040\u20134047. https:\/\/doi.org\/10.26355\/eurrev_202004_20875","DOI":"10.26355\/eurrev_202004_20875"},{"issue":"5","key":"6108_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL (2020) Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled. Multicenter Clinical Trial JAMA Neurol 77(5):582\u2013592. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"Multicenter Clinical Trial JAMA Neurol"},{"key":"6108_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","volume":"19","author":"S Muppidi","year":"2020","unstructured":"Muppidi S, Guptil JT, Jacob S, Li Y, Farrugia ME, Guidon AC et al (2020) COVID-19-associated risks and effects in Myasthenia gravis (CARE-MG). Lancet Neurol 19:970\u2013971. https:\/\/doi.org\/10.1016\/S1474-4422(20)30413-0","journal-title":"Lancet Neurol"},{"key":"6108_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","volume":"11","author":"AE Camelo-Filho","year":"2020","unstructured":"Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendon\u00e7a RH, Souza PVS et al (2020) Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes. Front Neurol 11:1053. https:\/\/doi.org\/10.3389\/fneur.2020.01053","journal-title":"Front Neurol"},{"key":"6108_CR8","doi-asserted-by":"publisher","unstructured":"Mimori M, Komatsu T, Maku T, Mitsumura H, Iguchi Y (2022) Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab. Neurol Sci 1\u20133. Online ahead of print. https:\/\/doi.org\/10.1007\/s10072-022-05922-2","DOI":"10.1007\/s10072-022-05922-2"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06108-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:08:32Z","timestamp":1660709312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06108-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6108"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06108-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,5,8]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}